Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth.

Pass RF, Nachman S, Flynn PM, Muresan P, Fenton T, Cunningham CK, Borkowsky W, McAuley JB, Spector SA, Petzold E, Levy W, Siberry GK, Handelsman E, Utech LJ, Weinberg A; IMPAACT 1089 Team..

J Pediatric Infect Dis Soc. 2013 Dec;2(4):352-60. doi: 10.1093/jpids/pit040. Epub 2013 Jul 17.

2.

Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children.

Phongsamart W, Sirisanthana V, Wittawatmongkol O, Maleesatharn A, Sudjaritruk T, Chearskul P, Aurpibul L, Sirisanthana T, Chokephaibulkit K.

Vaccine. 2011 Nov 3;29(47):8705-11. doi: 10.1016/j.vaccine.2011.08.101. Epub 2011 Sep 3.

PMID:
21893147
3.

Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.

Flynn PM, Nachman S, Muresan P, Fenton T, Spector SA, Cunningham CK, Pass R, Yogev R, Burchett S, Heckman B, Bloom A, Utech LJ, Anthony P, Petzold E, Levy W, Siberry GK, Ebiasah R, Miller J, Handelsman E, Weinberg A; IMPAACT P1088 Team..

J Infect Dis. 2012 Aug 1;206(3):421-30. doi: 10.1093/infdis/jis360. Epub 2012 May 21. Erratum in: J Infect Dis. 2012 Dec 15;206(12):1951.

4.

Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth.

Curtis DJ, Muresan P, Nachman S, Fenton T, Richardson KM, Dominguez T, Flynn PM, Spector SA, Cunningham CK, Bloom A, Weinberg A.

PLoS One. 2015 Mar 18;10(3):e0118567. doi: 10.1371/journal.pone.0118567. eCollection 2015.

5.

High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088).

Weinberg A, Muresan P, Fenton T, Richardson K, Dominguez T, Bloom A, Petzold E, Anthony P, Cunningham CK, Spector SA, Nachman S, Siberry GK, Handelsman E, Flynn PM; IMPAACT P1088 study team..

Hum Vaccin Immunother. 2013 May;9(5):957-68. doi: 10.4161/hv.23774. Epub 2013 Jan 31.

6.

Immune Responses to Circulating and Vaccine Viral Strains in HIV-Infected and Uninfected Children and Youth Who Received the 2013/2014 Quadrivalent Live-Attenuated Influenza Vaccine.

Weinberg A, Curtis D, Ning MF, Claypool DJ, Jalbert E, Patterson J, Frank DN, Ir D, Armon C.

Front Immunol. 2016 Apr 15;7:142. doi: 10.3389/fimmu.2016.00142. eCollection 2016.

7.

Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.

Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.

Pediatrics. 2006 Sep;118(3):e579-85.

PMID:
16950949
8.

Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals.

Ho J, Moir S, Wang W, Posada JG, Gu W, Rehman MT, Dewar R, Kovacs C, Sneller MC, Chun TW, Follmann DA, Fauci AS.

AIDS. 2011 Jan 28;25(3):295-302. doi: 10.1097/QAD.0b013e328342328b.

9.

Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.

Lagler H, Grabmeier-Pfistershammer K, Touzeau-Römer V, Tobudic S, Ramharter M, Wenisch J, Gualdoni GA, Redlberger-Fritz M, Popow-Kraupp T, Rieger A, Burgmann H.

PLoS One. 2012;7(5):e36773. doi: 10.1371/journal.pone.0036773. Epub 2012 May 21.

10.

Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?

Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.

Pediatrics. 2006 Sep;118(3):e570-8.

PMID:
16950948
11.

Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults.

Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A, Faix D, Defang G, Bai Y, Iverson E, Lalani T, Whitman T, Blair PJ, Brandt C, Macalino G, Burgess T.

Clin Infect Dis. 2011 Jan 1;52(1):138-46. doi: 10.1093/cid/ciq019. Epub 2010 Dec 7.

12.

High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.

Yam KK, Gipson E, Klein M, Walmsley S, Haase D, Halperin S, Scheifele D, Ward BJ, Cooper C.

J Clin Immunol. 2014 Aug;34(6):655-62. doi: 10.1007/s10875-014-0054-z. Epub 2014 May 14.

PMID:
24824648
13.

Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination.

Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP.

PLoS One. 2011 Jan 31;6(1):e16496. doi: 10.1371/journal.pone.0016496.

14.

Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.

Chen WH, Winokur PL, Edwards KM, Jackson LA, Wald A, Walter EB, Noah DL, Wolff M, Kotloff KL; Pandemic H1N1 Vaccine Adult Study Group..

Vaccine. 2012 Jun 13;30(28):4240-8. doi: 10.1016/j.vaccine.2012.04.044. Epub 2012 Apr 23.

15.

Safety, immunogenicity and shedding of LAIV4 in HIV-infected and uninfected children.

Curtis D, Ning MF, Armon C, Li S, Weinberg A.

Vaccine. 2015 Sep 11;33(38):4790-7. doi: 10.1016/j.vaccine.2015.07.082. Epub 2015 Aug 1.

PMID:
26241950
16.

Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.

Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeil S, Dobson S, Kellner JD, Kuhn S, Kollman T, MacKinnon-Cameron D, Smith B, Li Y, Halperin SA.

Vaccine. 2012 May 14;30(23):3389-94. doi: 10.1016/j.vaccine.2012.03.046. Epub 2012 Mar 30.

PMID:
22469860
17.

Immunogenicity and safety of an inactivate pandemic H1N1 vaccine provided by the Thai ministry of public health as a routine public health service.

Kankawinpong O, Sangsajja C, Cholapand A, Manosuthi W, Thientong V, Nuntapanich N, Rompotal P, Puthavathana P.

Southeast Asian J Trop Med Public Health. 2012 May;43(3):680-6.

PMID:
23077848
18.

The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children.

Okike IO, Yung C, Ladhani S, Oeser C, Bennett A, Doerholt K, Storey S, Donaghy S, Butter N, Hoschler K, Sheasby L, Heath PT, Miller E.

Vaccine. 2011 Sep 2;29(38):6636-40. doi: 10.1016/j.vaccine.2011.06.103. Epub 2011 Jul 13.

PMID:
21742005
19.

Evaluation of replication, immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in non-human primates.

Boonnak K, Paskel M, Matsuoka Y, Vogel L, Subbarao K.

Vaccine. 2012 Aug 17;30(38):5603-10. doi: 10.1016/j.vaccine.2012.06.088. Epub 2012 Jul 10.

20.

Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial.

ViganĂ² A, Giacomet V, Pariani E, Giani E, Manfredini V, Bedogni G, Erba P, Amendola A, Zanetti A, Zuccotti G.

Clin Vaccine Immunol. 2011 Sep;18(9):1503-9. doi: 10.1128/CVI.05200-11. Epub 2011 Jul 27.

Supplemental Content

Support Center